Special Interest Group

Formulation, Delivery & Manufacturing Special Interest Group from Vaccine Insights

Solving the development
and scale-up challenges
of next-generation vaccines

To hear when each 2027 output is published

REGISTER YOUR INTEREST

Interested in sponsoring the SIG?

FIND OUT MORE

Aim

The Vaccine Insights Special Interest Group (SIG) is an invitation-only initiative that brings senior experts together in small, closed-door working groups under the Chatham House Rule to build consensus, set priorities, and produce practical, open-access guidance for the field.

SIG members are invited from pharma, biotech, vaccine manufacturers, regulatory agencies, public health organizations, and academia to address one central question:

“What will it take to formulate, deliver, and manufacture the next generation of vaccines?”

Focus for 2027

COVID-19 showed how quickly new vaccine platforms can move from concept to global supply, but it also exposed the limits of current formulation, delivery, and manufacturing approaches. Lipid nanoparticles (LNPs) and adjuvants now underpin many next-generation candidates, from saRNA and combination vaccines to therapeutic cancer vaccines, yet stability, scale-up, analytical characterization, and supply remain persistent barriers. At the same time, advances in thermostable formulations, novel delivery routes, and platform and continuous manufacturing are changing what the field can realistically aim for, while biosecurity priorities and rapid-response targets are placing new demands on manufacturing capacity.

In its first year, the SIG will focus on four questions:

  • How can LNP and adjuvant formulations be designed, characterized, and supplied reliably for next-generation vaccines?
  • Which delivery routes and stability approaches can broaden access and reduce cold chain dependence, and what evidence do they still need?
  • How can manufacturing keep pace with new platforms and rapid-response demands?
  • How should analytics, potency testing, and CMC expectations keep pace with novel formulations?

Steering Committee & SIG members

The full list of the Steering Committee and SIG members will be published in early 2027.

Upcoming key dates and activities

The SIG’s work in 2027 centers on a series of closed-door working groups, taking place from 1 to 19 November. The Vaccine Insights editorial team then turns the consensus reached by members into a series of outputs published in the months that follow, setting out the field’s shared position and priorities.

2027 annual SIG:

1–19 November

The SIG opens with a keynote presentation, followed by a series of working groups over three weeks. SIG members will meet in nine closed-door working groups under the Chatham House Rule, and each group will agree consensus statements on its topic.

Working groups:

  • LNP design
  • Adjuvant selection, supply, and access
  • Mucosal and intradermal delivery, beyond the needle
  • Thermostability and single-administration vaccines
  • Continuous and intensified manufacturing
  • Rapid-response and surge manufacturing
  • Analytics and release for novel formulations
  • Potency assay design and standardization
  • CMC and regulatory readiness

All SIG members meet under the Chatham House Rule. Each working group will produce consensus statements, which will form the basis of the outputs below.

Infographic

Results from live polls of SIG members during the meeting.

Meeting report

A full open-access meeting report with strategic recommendations for the field.

White paper

A peer-reviewed white paper on a priority topic identified by the group.

Further activities

These may include webinars, articles, in-person SIG member gatherings, and report-outs at major vaccine conferences.

To be kept informed about the progression and development of the SIG outputs, please register your interest.

REGISTER YOUR INTEREST